ACHVAchieve Life Sciences, Inc.
Achieve Life Sciences, Inc. (ACHV) develops and commercializes cytisinicline, a nicotine dependence treatment, with a focus on the U.S. market. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to deliver revenue and earnings guidance amid ongoing clinical and commercial execution.
- The company has a $21.52M shareholders’ equity and reported $0 revenue in 2026, with $76.35M free cash flow (TTM) deficit.
- Net loss of $109.55M in 2026, with diluted EPS of -0.80, reflects a heavily leveraged capital structure.
- No peer events directly collide with ACHV’s earnings release, though Amgen Inc. and Gilead Sciences, Inc. will report Q3 2026 results around the same time.
The schedule
- Thu5Nov
The earnings release will test the company's ability to deliver consistent revenue and margin improvements, following a recent cash runway update that highlighted liquidity concerns. This differs from the last print where guidance cuts overshadowed revenue growth.
- Thu4Feb
This release will test the company's ability to maintain revenue momentum and improve cash flow conversion, especially after the last print where guidance cuts and margin compression led to a sharp decline.
- Mon10May
The earnings release will test the company's ability to deliver strong revenue growth and improved cash flow, following a recent cash runway update that raised concerns about liquidity. This differs from the last print where guidance cuts overshadowed revenue growth.
- Mon9Aug
This release will test the company's ability to maintain revenue momentum and improve cash flow conversion, especially after the last print where guidance cuts and margin compression led to a sharp decline.
Past
- Tue12May
Actual outcome: Bear · $4.69 at outcome
Although Achieve Life Sciences reported in-line Q1 EPS and secured a massive $354 million financing package to resolve its cash runway concerns, the stock fell 21.7% following the update. The sharp sell-off was driven by the disclosure of FDA inspection issues at a third-party manufacturer, which is expected to trigger a Complete Response Letter (CRL) and delay the cytisinicline NDA resubmission to Q4 2026.
ACHV's Q1 print comes with the stock at $5.99 and extremely overbought (RSI 77.6). Management must address the $28M cash position against an accelerating pre-commercial burn.